Lista de obras - Shannon Meeks - Dominio Público Uruguay

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function

artículo científico publicado en 2012

A microengineered vascularized bleeding model that integrates the principal components of hemostasis.

artículo científico publicado en 2018

A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

artículo científico publicado en 2016

Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment

artículo científico publicado en 2008

Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

artículo científico publicado en 2018

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation

artículo científico publicado en 2007

Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies

artículo científico publicado en 2013

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene

artículo científico publicado en 2015

Development of factor VIII inhibitors in two patients with moderate haemophilia A.

artículo científico publicado en 2012

Discordance between platelet-supported and vesicle-supported factor VIII activity in the presence of anti-C2 domain inhibitory antibodies

scientific article published on 17 June 2020

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy

scientific article published on 03 September 2020

Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

artículo científico publicado en 2016

Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

artículo científico publicado en 2013

Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.

artículo científico publicado en 2011

Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

artículo científico publicado en 2014

Factor II, Factor V and Factor X Deficiencies

Factor VII Deficiency

Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein

artículo científico publicado en 2011

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation

artículo científico publicado en 2020

Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.

artículo científico publicado en 2016

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors

artículo científico publicado en 2016

High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance

artículo científico publicado en 2014

Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis

artículo científico publicado en 2019

Innovating immune tolerance induction for haemophilia.

artículo científico publicado en 2016

Late immune tolerance induction in haemophilia A patients.

artículo científico publicado en 2013

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

artículo científico publicado en 2017

Medical radiation exposure in children with bleeding disorders: an institutional experience.

artículo científico

Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

artículo científico publicado en 2009

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors

artículo científico publicado en 2008

Platelet-Microcapsule Hybrids Leverage Contractile Force for Targeted Delivery of Hemostatic Agents.

artículo científico publicado en 2017

Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition

artículo científico publicado en 2012

Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice

artículo científico publicado en 2019

Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach.

artículo científico publicado en 2015

Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates

artículo científico publicado en 2006

Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes

artículo científico publicado en 2013

The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces

artículo científico publicado en 2015

The diversity of the immune response to the A2 domain of human factor VIII

artículo científico publicado en 2013

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors

scientific article published on 05 September 2019

The national blueprint for future basic and translational research to understand factor VIII immunogenicity: NHLBI State of the Science Workshop on factor VIII inhibitors

artículo científico publicado en 2019

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development

artículo científico publicado en 2020

Toward optimal therapy for inhibitors in hemophilia

artículo científico publicado en 2014

Toward optimal therapy for inhibitors in hemophilia.

artículo científico publicado en 2014

US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors

artículo científico

Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.

artículo científico publicado en 2014

Lista de obras de Shannon Meeks

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function

A microengineered vascularized bleeding model that integrates the principal components of hemostasis.

A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment

Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation

Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene

Development of factor VIII inhibitors in two patients with moderate haemophilia A.

Discordance between platelet-supported and vesicle-supported factor VIII activity in the presence of anti-C2 domain inhibitory antibodies

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy

Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.

Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

Factor II, Factor V and Factor X Deficiencies

Factor VII Deficiency

Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation

Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors

High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance

Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis

Innovating immune tolerance induction for haemophilia.

Late immune tolerance induction in haemophilia A patients.

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

Medical radiation exposure in children with bleeding disorders: an institutional experience.

Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors

Platelet-Microcapsule Hybrids Leverage Contractile Force for Targeted Delivery of Hemostatic Agents.

Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition

Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice

Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach.

Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates

Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes

The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces

The diversity of the immune response to the A2 domain of human factor VIII

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors

The national blueprint for future basic and translational research to understand factor VIII immunogenicity: NHLBI State of the Science Workshop on factor VIII inhibitors

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development

Toward optimal therapy for inhibitors in hemophilia

Toward optimal therapy for inhibitors in hemophilia.

US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors

Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.